Rockwell Medical (RMTI) Presents At 26th Annual NewsMakers In The Biotech Industry - Slideshow

Triferic Product & Market Opportunity - Triferic is the FIRST and ONLY FDA-approved therapy indicated to maintain hemoglobin levels in hemodialysis patients[5, 66] - Global Triferic market potential exceeds $1 billion[5, 10, 51, 52] - The U S market potential for Triferic is estimated at $400 million[47] - The company's base business generates over $60 million in revenue annually[5] Commercialization & Strategy - Dialysate Triferic U S commercial launch commenced in May 2019, establishing a foundation for I V Triferic[5, 14] - I V Triferic NDA was submitted in May 2019 with a PDUFA date of March 28, 2020[5, 14, 33] - The company is building a commercial and medical team of approximately 25 professionals to support Triferic adoption[41] Financial Performance - The company's sales were $63 4 million in FY 2018 and $57 3 million in FY 2017[56] - The operating loss was $32 4 million in FY 2018 and $25 9 million in FY 2017[57] - The company's cash and investments were $33 5 million[59]